Physician profile
Devra Hamilton
NPI 1225354616
$10,297.66
in general payments reported to CMS, 2019-2025
39 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,976 · 2022: $3,090 · 2023: $2,308 · 2024: $1,723 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.40 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,594.25 | 2021-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $1,050.61 | 2021-2025 | |
| Amgen INC. | $795.17 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $717.51 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $560.83 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $489.27 | 2021-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $489.19 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.53 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $433.52 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $406.48 | 2021-2024 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $393.08 | 2021-2024 | Nexletol |
| Ironwood Pharmaceuticals, INC | $322.34 | 2021-2024 | Linzess |
| Glaxosmithkline, LLC. | $283.76 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $277.48 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $268.98 | 2021-2024 | Mounjaro, Jardiance, Emgality |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devra Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.